Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Latest news and events
Oct 15, 2019
Pneumagen Ltd Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Meet the team
Douglas Thomson
Chief Executive Officer
Dr Helen Connaris
Chief Scientific Officer
Professor Garry Taylor
Director and Chairman of Scientific Advisory Board
Thomas Engelen
Non-executive Chairman